
Wednesday, May 28, 2025 8:37:53 AM
May 28, 2025
To My Fellow Shareholders,
As a long-term shareholder and advocate for transparency and accountability, I believe it is important to address a critical issue that has recently come to light—and to clarify the timeline and roles involved.
First and foremost, it must be clearly understood that Music Licensing, Inc. ($SONG) existed prior to the formation of the associated family office. This fact is not incidental; it is central to the governance and fiduciary responsibilities owed to all shareholders. The formation of any advisory or affiliated entity does not—and should not—supersede or obscure the obligations tied to $SONG’s operational and equity integrity.
In recent weeks, I have communicated directly with Jake regarding serious concerns about the apparent sale and circulation of shares. I was explicitly told that no shares were being sold, nor were any held in a custodial account. Yet, subsequent trading activity and market records strongly suggest otherwise. If shares are being sold, I—and all shareholders—deserve to know:
• Who is selling them?
• Under what authority?
• Where is the money going?
These are not small discrepancies. They strike at the heart of shareholder rights and corporate oversight.
Due to the unresolved nature of these concerns, I have formally communicated these issues to regulatory authorities. I believe full transparency is not just warranted—it is necessary to preserve the credibility of the company and protect its rightful owners.
This letter is not an accusation; it is a call for answers. The integrity of Music Licensing, Inc. depends on our collective commitment to fiduciary duty, lawful transparency, and responsible stewardship of shareholder value.
I am prepared to work constructively with all relevant parties to uncover the facts and pursue a resolution that reflects the values we should all expect from a public company.
Sincerely,
The Golden One
Recent SONG News
- Form 1-U - Current Report Pursuant to Regulation A • Edgar (US Regulatory) • 01/17/2025 02:38:16 PM
- Form 1-U - Current Report Pursuant to Regulation A • Edgar (US Regulatory) • 12/12/2024 01:03:09 PM
- Form 1-U - Current Report Pursuant to Regulation A • Edgar (US Regulatory) • 12/09/2024 02:03:02 PM
- Form 1-U - Current Report Pursuant to Regulation A • Edgar (US Regulatory) • 12/02/2024 01:02:02 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM